CD40 and neoplasm: The results demonstrated that a combinatorial therapy of CD40 agonist and anti‐PD‐1 ICB was found to improve survival in CT2A tumour‐bearing mice, indicating that dysfunctional CD4+ T cells were correlated with Tex‐term and CD4+ T cells played a role in the efficacy of anti‐PD‐1 ICB by controlling the severity of exhaustion.